Cerity Partners LLC Makes New $654,000 Investment in Janux Therapeutics, Inc. (NASDAQ:JANX)

Cerity Partners LLC purchased a new stake in Janux Therapeutics, Inc. (NASDAQ:JANX) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 60,933 shares of the company’s stock, valued at approximately $654,000. Cerity Partners LLC owned 0.13% of Janux Therapeutics as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the company. Nisa Investment Advisors LLC grew its stake in Janux Therapeutics by 10,740.0% in the fourth quarter. Nisa Investment Advisors LLC now owns 2,710 shares of the company’s stock valued at $29,000 after acquiring an additional 2,685 shares during the period. China Universal Asset Management Co. Ltd. acquired a new position in shares of Janux Therapeutics in the 4th quarter valued at approximately $57,000. SG Americas Securities LLC bought a new stake in Janux Therapeutics during the 4th quarter worth approximately $100,000. Old Well Partners LLC acquired a new stake in Janux Therapeutics during the 3rd quarter worth approximately $104,000. Finally, Corton Capital Inc. bought a new position in Janux Therapeutics in the third quarter valued at approximately $111,000. Institutional investors own 75.39% of the company’s stock.

Janux Therapeutics Price Performance

Shares of NASDAQ JANX opened at $49.78 on Wednesday. Janux Therapeutics, Inc. has a fifty-two week low of $5.65 and a fifty-two week high of $58.69. The stock has a market capitalization of $2.57 billion, a price-to-earnings ratio of -37.15 and a beta of 4.19. The business has a 50-day moving average of $36.84 and a 200-day moving average of $18.77.

Janux Therapeutics (NASDAQ:JANX) last posted its quarterly earnings results on Friday, March 8th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.37) by $0.12. Janux Therapeutics had a negative net margin of 721.18% and a negative return on equity of 17.88%. The firm had revenue of $2.46 million for the quarter, compared to analyst estimates of $0.98 million. On average, sell-side analysts expect that Janux Therapeutics, Inc. will post -1.41 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on JANX shares. Bank of America increased their price objective on shares of Janux Therapeutics from $24.00 to $48.00 and gave the stock a “buy” rating in a research report on Wednesday, March 13th. BTIG Research started coverage on Janux Therapeutics in a research note on Thursday, March 21st. They issued a “buy” rating and a $62.00 price target on the stock. Jonestrading started coverage on Janux Therapeutics in a report on Tuesday, April 16th. They issued a “buy” rating and a $70.00 price target on the stock. Wedbush reiterated an “outperform” rating and set a $53.00 price objective on shares of Janux Therapeutics in a report on Monday, March 11th. Finally, Cantor Fitzgerald assumed coverage on Janux Therapeutics in a research report on Wednesday, March 20th. They issued an “overweight” rating and a $100.00 target price on the stock. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $61.33.

Janux Therapeutics Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.